Business
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
SHANGHAI & SUZHOU, China, October 22, 2025--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a collaboration agreement with Shanghai Henlius Biotech, Inc., (2696.HK) ("Henlius") to develop innovative cancer immunotherapy with an engineered cytokine.
About this update from Shanghai Henlius Biotech, Inc. Class H
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/631841a320335a7312403e508c5142ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3xfa2Z6mf9JFSJu6XFiSOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/631841a320335a7312403e508c5142ae","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pzEhboeZ2hBuVdy__jR0PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/631841a320335a7312403e508c5142ae","width":1024,"height":512}},"lazy":false},{"type":"text","content":"SHANGHAI & SUZHOU, China, October 22, 2025--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a collaboration agreement with Shanghai Henlius Biotech, Inc., (2696.HK) ("Henlius") to develop innovative cancer immunotherapy with an engineered cytokine.","length":423,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Forlong will fuse a monoclonal antibody against a specific target selected by Henlius in a site-specific manner, with an engineered cytokine. In exchange, Forlong will receive an undisclosed upfront sponsor fee and research milestone payments, and upon reaching a predetermined development milestone, further licensing fee payments.","length":366,"tagName":"p"},{"type":"text","content":"Forlong has developed a portfolio of engineered cytokines aiming to activate specific subpopulations of the immune system. FL115 is an interleukin-15 (IL-15) superagonist to stimulate natural killer (NK) cells and memory T cells, showing favorable safety profile and preliminary clinical responses in multiple Phase I studies in China and US, and is currently being advanced to combo therapy with PD-(L)1 antibodies in Phase I for patients with advanced solid tumors and combo therapy with Bacillus Calmette-Guérin (BCG) in Phase II for patients with nonmuscle invasive bladder cancer (NMIBC). FL116 is a human anti-programmed cell death protein 1 (PD-1) antibody site-specifically fused to an interleukin-18 (IL-18) variant ...